Ervin CM, Mangel AW. Clinical trials in irritable bowel syndrome: a review. Rev Recent Clin Trials. 2013 Mar 1;8(1):9-22.
Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pages M, Torres F, Maurel J. Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD). Rev Recent Clin Trials. 2011 May;6(2):158-70. doi: 10.2174/157488711795177868
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.
Sorensen HT, Steffensen FH, Sabroe S, Rothman KJ, Gillman MW, Fischer P. Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life. West J Med. 1999 Jan 1;170(5):260-2.